1. Fonner VA, Dalglish SL, Kennedy CE, et Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30:1973-83.
  2. Haberer Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS 2016;11:10-7.
  3. Van Damme L, Corneli A, Ahmed K, et Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411–22.
  4. Marrazzo JM, Ramjee G, Richardson BA, et Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 20
  5. Deutsch MB, Glidden DV, Sevelius J, et al; iPrEx investigators. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx Lancet HIV 2015;2:e512-9.
  6. Yun K, Xu JJ, Zhang J, et Female and younger subjects have lower adherence in PrEP trials: a meta- analysis with implications for the uptake of PrEP service to prevent HIV. Sex Transm Infect 2018;94:163-8.
  7. Hosek SG, Rudy B, Landovitz R, et al; Adolescent Trials Network (ATN) for HIVAIDS An HIV preexposure prophylaxis demonstration project and safety study for young MSM.J Acquir Immune Defic Syndr 2017;74:21
  8. Hosek SG, Landovitz RJ, Kapogiannis B, et Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr 2017;171:1063-71.
  9. Zablotska IB, Vaccher SJ, Bloch M, et al; PrELUDE Study High Adherence to HIV pre-exposure prophylaxis and no HIV seroconversions despite high levels of risk behaviour and STIs: the Australian Demonstration Study PrELUDE. AIDS Behav 2019;23:1780-9.
  10. Grulich AE, Guy R, Amin J, et al; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 2018;5:e629-37.
  11. Lal L, Audsley J, Murphy DA, et al; VicPrEP Study Team. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis AIDS 2017;31:1709-14.
  12. Traeger MW, Cornelisse VJ, Asselin J, et al; PrEPX Study T Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019;321:1380-90.
  13. Kesler MA, Kaul R, Myers T, et Perceived HIV risk, actual sexual HIV risk and willingness to take pre- exposure prophylaxis among men who have sex with men in Toronto, Canada. AIDS Care 2016;28:1–8.
  14. Grant RM, Lama JR, Anderson PL, et Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–99.
  15. Thigpen MC, Kebaabetswe PM, Paxton LA, et Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34.
  16. Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 Lancet 2013;381:2083–90.
  17. King HL, Keller SB, Giancola MA, et Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE study). AIDS Behav 2014;18:1722–5.
  18. Amico KR, Miller J, Balthazar C, et Integrated next step counseling (iNSC) for sexual health and PrEP use among young men who have sex with men: implementation and observations from ATN110/113. AIDS Behav 2019;23:1812-23.
  19. Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence? BMC Infect Dis 2018;18:581.
  20. Bradley E, Forsberg K, Betts JE, et Factors affecting pre-exposure prophylaxis implementation for women in the United States: a systematic review. J Womens Health (Larchmt) 2019 Jun 10.[Epub ahead of print]
  1. Haberer JE, Baeten JM, Campbell J, et Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.PLoS Med 2013;10:e1001511.
  1. Mutua G, Sanders E, Mugo P, et Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 2012;7:e33103.
  2. Grov C, Rendina HJ, John SA, Parsons Determining the roles that club drugs, marijuana, and heavy drinking play in PrEP medication adherence among gay and bisexual men: implications for treatment and research. AIDS Behav 2019;23:1277-86.
  3. Krakower D, Maloney KM, Powell VE, et Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc 2019;22:e25250.
  4. Marcus JL, Buisker T, Horvath T, et Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med 2014;15:385-95.
  5. World Health Organization. Technical brief. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral July 2019. Available at: 19.8-eng.pdf?ua=1 (last accessed 24 August 2019).